Research

Global Trials

The ISN-ACT Global Trials Focus team has collected and published a new list of randomized research from nephrologists around the world for August 2020. Each trial is reviewed in context and the risk of bias in seven key areas is assessed. Highlight: Allopurinol does not slow the progression of chronic kidney disease in patients with type 1...

Discover the Latest on DAPA-CKD: Dapagliflozin in Patients with Chronic Kidney Disease

The full DAPA-CKD trial results will be presented and reviewed at the ESC Congress 2020, Sunday, August 30, 17:00 – 17:30 CET. Topic Renal failure and Cardiovascular Disease Chairpersons Rory Collins (Oxford, UK); Frank Ruschitzka (Zurich, Switzerland) Presentations: DAPA-CKD – Dapagliflozin in Patients with CKD: Hiddo Heerspink (Groningen, Netherlands) DAPA- CKD – Live Prime Discussion: Diederick E Grobbee (Utrecht, Netherlands) Q&A Session The...

CORONATION Registry: Contribute Data on Kidney Patients with COVID-19 from your Region

The ISN invites nephrologists to register patients affected by COVID-19 on the new  global COVID registry. The ISN collaborated with the University of Cambridge to develop CORONATION, the Coronavirus multinational observational registry, a data entry portal accessible to nephrologists worldwide to collect anonymous data on individual people with kidney disease and the COVID-19 infection. For more information, please visit...

Coming Soon: Kidney International to Publish International Consensus Definitions of Clinical Trial Outcomes for Kidney Failure

Kidney International will shortly publish the International Consensus Definitions of Clinical Trial Outcomes for Kidney Failure: 2020, developed from the 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials hosted by the ISN in Vancouver, BC, Canada, in early 2020. This is the first attempt by the international nephrology community to identify reproducible,...

Global Trials

Every month the ISN-ACT Team lists interesting new randomized controlled trials from around the world. Highlight: Early ACE-inhibition is safe in pediatric Alport’s Syndrome and may be effective See the latest trials here

The ISN-ACT Committee Releases Statement to Encourage the Inclusion of Kidney Patients in Research Activities.

The International Society of Nephrology urges all investigators and industry partners to include people with kidney diseases in research activities related to COVID-19. The ISN-ACT (Advancing Clinical Trials) Committee has released a statement on the urgent need to include patients with kidney diseases in clinical trials related to COVID-19. Despite preliminary studies demonstrating the increased risk...